| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0001836 | Release of cytochrome c from mitochondria | Increases phenotype | PMID:28390674 |
| GO:0004069 | L-aspartate:2-oxoglutarate aminotransferase activity | Increases phenotype | PMID:36450499 |
| GO:0004683 | Calmodulin-dependent protein kinase activity | Increases phenotype | PMID:34286406 |
| GO:0004784 | Superoxide dismutase activity | Increases phenotype | PMID:29548726 |
| GO:0006309 | Apoptotic dna fragmentation | Increases phenotype | PMID:14505808; PMID:28390674 |
| GO:0006749 | Glutathione metabolic process | Affects phenotype | PMID:36646412 |
| GO:0006750 | Glutathione biosynthetic process | Affects phenotype | PMID:28257953; PMID:28390674 |
| GO:0006979 | Response to oxidative stress | Increases phenotype | PMID:31532279 |
| GO:0007204 | Positive regulation of cytosolic calcium ion concentration | Increases phenotype | PMID:28919489 |
| GO:0007612 | Learning | Decreases phenotype | PMID:29233033 |
| GO:0008219 | Cell death | Increases phenotype | PMID:11361008; PMID:22770624; PMID:28257953; PMID:28390674; PMID:29408665; PMID:30779908; PMID:7953637 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:14505808; PMID:22770624; PMID:28257953 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:30399392 |
| GO:0008291 | Acetylcholine metabolic process | Affects phenotype | PMID:29233033 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:28919489 |
| GO:0019233 | Sensory perception of pain | Increases phenotype | PMID:29129814 |
| GO:0031987 | Locomotion involved in locomotory behavior | Decreases phenotype | PMID:29233033 |
| GO:0032464 | Positive regulation of protein homooligomerization | Increases phenotype | PMID:29298433 |
| GO:0035640 | Exploration behavior | Decreases phenotype | PMID:29233033 |
| GO:0043525 | Positive regulation of neuron apoptotic process | Increases phenotype | PMID:30768131 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:35027733 |
| GO:0046330 | Positive regulation of jnk cascade | Increases phenotype | PMID:30768131 |
| GO:0046466 | Membrane lipid catabolic process | Increases phenotype | PMID:31532279 |
| GO:0061366 | Behavioral response to chemical pain | Increases phenotype | PMID:29129814 |
| GO:0070994 | Detection of oxidative stress | Increases phenotype | PMID:36646412 |
| GO:0070997 | Neuron death | Increases phenotype | PMID:27722792 |
| GO:0071902 | Positive regulation of protein serine/threonine kinase activity | Increases phenotype | PMID:34286406 |
| GO:1901856 | Negative regulation of cellular respiration | Increases phenotype | PMID:33320250 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:14505808 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.